[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614457":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":24,"locations":10,"responsibleParty":33,"collaborators":10,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":39,"acronym":10,"eligibilityCriteria":40,"healthyVolunteers":37,"sex":41,"minAge":42,"maxAge":43,"enrollmentInfo":44,"targetDuration":10,"studyType":47,"phases":10,"briefSummary":48,"conditions":49,"keywords":10,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":10},{"fullName":5,"class":6},"Anhui Provincial Hospital","OTHER_GOV",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Subjects who have previously participated in RGL-193-related studies and have received RGL-193 treat",null,[12],"Other: Observational",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"OTHER","Observational","Long-term observational",[9],[20],{"name":21,"affiliation":22,"role":23},"Chaoshi Niu","The First Affiliated Hospital of University of Science and Technology of China","PRINCIPAL_INVESTIGATOR",[25,29],{"name":21,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","+86 13855186208","niuchaoshi@163.com",{"name":30,"role":26,"phone":31,"phoneExt":10,"email":32},"Chi Xiong","+86 18709857411","xiongchi@ustc.edu.cn",{"type":34,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100614457","an-open-label-observational-long-term-follow-up-study-evaluating-the-safety-and-efficacy-of-rgl-193-putamen-injection-in-patients-with-primary-parkinsons-disease-100614457",false,"NCT07279844","An Open-label, Observational, Long-term Follow-up Study Evaluating the Safety and Efficacy of RGL-193 Putamen Injection in Patients With Primary Parkinson's Disease","Inclusion Criteria:\n\n1. Subjects who have previously participated in RGL-193-related studies and have received RGL-193 treatment；\n2. Those who voluntarily participate in this trial and sign a written informed consent form -\n\nExclusion Criteria:\n\nNone\n\n\\-","ALL","45 Years","70 Years",{"count":45,"type":46},6,"ESTIMATED","OBSERVATIONAL","To evaluate the long-term safety of RGL-193 capsid injection in patients with primary Parkinson's disease over 5 years",[50],"Parkinson's Disease","NOT_YET_RECRUITING","2025-12-01",{"date":54,"type":55},"2025-12-12","ACTUAL",{"date":57,"type":46},"2025-12-15",{"date":59,"type":46},"2029-12-14",{"name":5,"class":6}]